Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
SGLT2 Inhibitors for Type 2 Diabetes with CKD Stage 3b-4
Recruiting1 award9 criteria
Dallas, Texas
This trial is designed to see if Effervescent calcium magnesium citrate (EffCaMgCitrate) and dapagliflozin have an effect on surrogate markers of kidney and cardiovascular health in patients with stage 3b-4 Chronic Kidney Disease (CKD). 30 patients will be recruited and randomly assigned to one of three groups: placebo, CaMgcitrate 480mg Mg, or dapagliflozin 10mg. The trial will last 24 weeks.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service